Lumexa Imaging enters its third-quarter report with a story that improved materially last time but has not yet been rewarded. The second quarter delivered a record $23.1 million in free cash flow, net leverage of 3.6 times, a record share of high-value advanced imaging and a marquee joint venture with Hospital for Special Surgery. Yet management only narrowed its outlook rather than raising it, and adjusted EBITDA margin still trailed the prior year. The November 10 release, due after the close, is the first real test of whether those improvements translate into earnings leverage.
The Street is looking for $0.20 per share on revenue of $269.0 million, up modestly from $264.2 million in the second quarter. The earnings bar is more demanding than the revenue bar: consensus implies EPS doubling from last quarter's $0.10. The whisper number sits a couple of cents higher at $0.22, a sign that some traders expect the bottom line to clear consensus, though the gap is small. For the full year, management reaffirmed adjusted EPS of $0.71 to $0.77 and revenue of $1.045 billion to $1.097 billion. Consensus at $0.76 sits near the top of the earnings range, while the $1.07 billion revenue estimate is close to the midpoint. That combination means analysts are counting on margin improvement, not just volume, to carry the back half of the year.
Several pieces of the prior call support that expectation. The June term loan repricing to SOFR plus 250 basis points begins saving roughly $4 million a year this quarter, a modest but tangible boost below the operating line. Two of three new PET machines went live in July, so the third quarter is the first full period with expanded capacity in a modality that grew more than 23% in each of the first two quarters. If PET growth holds or accelerates and advanced modality mix pushes past 37.4% of volume, that would validate management's argument that mix can offset the step-up in public company costs and de novo spending. Continued recovery in mammography after its weather-hit first quarter would add support.
The risks are equally specific. Operating expenses rose about 5% last quarter amid tight radiologist and technologist labor, and a further climb could absorb the mix benefit. Management called a slight dip in commercial payer mix, around 59%, immaterial; any further slippage would challenge that view because commercial reimbursement drives profitability. Cash flow also needs scrutiny. The second quarter's 41% EBITDA conversion came partly from debt paydown and lower interest, and a sharp reversion would raise doubts about how durable the deleveraging story is. On growth, the HSS partnership will not contribute meaningfully until 2027 because of New York certificate of need requirements, so evidence of progress will come from the first UPMC site, commentary on the roughly 100-system partnership pipeline and any update on how site-neutrality proposals are shaping hospital conversations.
Sentiment has swung notably, moving from bearish heading into the last report to solidly bullish now. The stock has not followed, falling 5.4% since the second-quarter release versus a 2.9% decline for the S&P 500. At $11.15 it sits essentially on its 200-day moving average and below the middle of its post-earnings range of $9.83 to $13.00, a far calmer band than the prior quarter's swing from $6.45 to $12.93.
The central question is whether margins finally turn the corner. A sequential improvement in adjusted EBITDA margin, paired with steady cash generation and confidence in the full-year range, would show that the PET ramp and refinancing are doing their job. Another narrowing with flat margins would suggest consensus near the top of guidance is getting ahead of the business.